[Drugs in development for the treatment of osteoporosis: Tibolone].
Gorai
Itsuo
I
Department of Obstetrics and Gynecology, Yokohama City University School of Medicine.
D000818:Animals; D015519:Bone Density; D004714:Endometrial Hyperplasia / Q000139:chemically induced; D005260:Female; D006801:Humans; D009652:Norpregnenes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009928:Organ Specificity; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D011944:Receptors, Androgen / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D009652:Norpregnenes; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C027385:tibolone